Servier’s muscular dystrophy drug sevasemten failed to slow a rare form of Becker muscular dystrophy in a long placebo-controlled Phase 3 trial, according to a report based on the company’s statement. Servier had paid $1.55 billion upfront for the asset originally developed by Edgewise Therapeutics, plus additional potential milestones. The pivotal GRAND CANYON trial’s results were described as not aligned with earlier findings, leading Servier to conduct a comprehensive analysis of the dataset alongside prior clinical information. The failure is a setback for patients in a condition with no approved treatments. For the industry, the outcome illustrates how late-stage divergence between smaller studies and pivotal endpoints can quickly reset expectations for highly capitalized acquisitions.